Oslo, Norway, 19 March 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin^®, the Company's lead product candidate, marking the first approval worldwide within this patent family.

The newly granted patent covers a key technical development to optimize Radspherin's^® performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin^® in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition-of-matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide.

"We are very pleased to obtain this additional patent in China for Radspherin^®," said Oystein Soug, Chief Executive Officer at Oncoinvent. "As we continue to advance clinical development, it is essential that our innovation is backed by a strong and durable global intellectual property position."